Amin Kamel

1.3k total citations
40 papers, 998 citations indexed

About

Amin Kamel is a scholar working on Molecular Biology, Pharmacology and Spectroscopy. According to data from OpenAlex, Amin Kamel has authored 40 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Pharmacology and 13 papers in Spectroscopy. Recurrent topics in Amin Kamel's work include Pharmacogenetics and Drug Metabolism (13 papers), Analytical Chemistry and Chromatography (12 papers) and Drug Transport and Resistance Mechanisms (8 papers). Amin Kamel is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Analytical Chemistry and Chromatography (12 papers) and Drug Transport and Resistance Mechanisms (8 papers). Amin Kamel collaborates with scholars based in United States, Switzerland and China. Amin Kamel's co-authors include Chandra Prakash, Burnaby Munson, Alaa-Eldin F. Nassar, Phyllis R. Brown, Shawn Harriman, Keith D. Wilner, Hassan G. Fouda, Donald Tweedie, J. Miceli and Donghui Cui and has published in prestigious journals such as Nucleic Acids Research, Analytical Chemistry and Biological Psychiatry.

In The Last Decade

Amin Kamel

39 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amin Kamel United States	17	378	291	250	113	104	40	998
John A. Masucci United States	19	455 1.2×	162 0.6×	272 1.1×	104 0.9×	93 0.9×	50	1.0k
JoAnn Scatina United States	22	483 1.3×	681 2.3×	210 0.8×	318 2.8×	85 0.8×	56	1.6k
Rasmy Talaat United States	19	437 1.2×	275 0.9×	289 1.2×	114 1.0×	58 0.6×	29	980
Kimberley A. Lentz United States	14	199 0.5×	125 0.4×	139 0.6×	305 2.7×	108 1.0×	24	963
John C. L. Erve United States	17	371 1.0×	367 1.3×	226 0.9×	140 1.2×	110 1.1×	26	1.0k
Nobuo Inotsume Japan	17	212 0.6×	243 0.8×	208 0.8×	221 2.0×	69 0.7×	90	1.1k
L. P. C. Delbressine Netherlands	19	422 1.1×	297 1.0×	235 0.9×	203 1.8×	261 2.5×	39	1.7k
Jean‐Paul Thénot United States	18	159 0.4×	209 0.7×	282 1.1×	110 1.0×	57 0.5×	38	1.1k
Christine Beedham United Kingdom	21	713 1.9×	561 1.9×	96 0.4×	87 0.8×	76 0.7×	32	1.4k
Chungang Gu United States	16	721 1.9×	403 1.4×	355 1.4×	154 1.4×	89 0.9×	46	1.6k

Countries citing papers authored by Amin Kamel

Since Specialization

Citations

This map shows the geographic impact of Amin Kamel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amin Kamel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amin Kamel more than expected).

Fields of papers citing papers by Amin Kamel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amin Kamel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amin Kamel. The network helps show where Amin Kamel may publish in the future.

Co-authorship network of co-authors of Amin Kamel

This figure shows the co-authorship network connecting the top 25 collaborators of Amin Kamel. A scholar is included among the top collaborators of Amin Kamel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amin Kamel. Amin Kamel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kamel, Amin, et al.. (2023). Pharmacokinetics and Absorption, Distribution, Metabolism and Excretion of RGLS4326 in Mouse and Monkey, an Anti–miR-17 Oligonucleotide for the Treatment of Polycystic Kidney Disease. Drug Metabolism and Disposition. 51(11). 1536–1546. 10 indexed citations

Kamel, Amin, et al.. (2020). In Vitro Metabolism of Slowly Cleared G Protein–Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism. Drug Metabolism and Disposition. 49(2). 121–132. 11 indexed citations

Gunduz, Mithat, et al.. (2012). Oxidative ipso Substitution of 2,4-Difluoro-benzylphthalazines: Identification of a Rare Stable Quinone Methide and Subsequent GSH Conjugate. Drug Metabolism and Disposition. 40(11). 2074–2080. 10 indexed citations

Obach, R. Scott, Chandra Prakash, & Amin Kamel. (2012). Reduction and methylation of ziprasidone by glutathione, aldehyde oxidase, and thiol s-methyltransferase in humans: anin vitrostudy. Xenobiotica. 42(11). 1049–1057. 16 indexed citations

Kamel, Amin, et al.. (2012). In vitrometabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan. Xenobiotica. 43(4). 368–378. 1 indexed citations

Kamel, Amin, et al.. (2011). In vitro-in vivocorrelation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict thein vivoclearance for compounds metabolized by monoamine oxidase. Xenobiotica. 42(4). 355–362. 10 indexed citations

Miller, Emily, David B. Duignan, Joanne Brodfuehrer, et al.. (2010). Understanding the clinical pharmacokinetics of a GABA_Apartial agonist by application ofin vitrotools. Xenobiotica. 40(7). 476–484. 4 indexed citations

Kamel, Amin, et al.. (2010). Metabolism, Pharmacokinetics, and Excretion of the 5-Hydroxytryptamine1B Receptor Antagonist Elzasonan in Humans. Drug Metabolism and Disposition. 38(11). 1984–1999. 7 indexed citations

Kamel, Amin, et al.. (2010). Metabolism, pharmacokinetics and excretion of the GABA_Areceptor partial agonist [¹⁴C]CP-409,092 in rats. Xenobiotica. 40(6). 400–414. 8 indexed citations

10.

Kamel, Amin, et al.. (2007). Metabolism, Pharmacokinetics, and Excretion of the Substance P Receptor Antagonist CP-122,721 in Humans: Structural Characterization of the Novel Major Circulating Metabolite 5-Trifluoromethoxy Salicylic Acid by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and NMR Spectroscopy. Drug Metabolism and Disposition. 35(6). 884–897. 7 indexed citations

11.

Kamel, Amin & Chandra Prakash. (2006). High Performance Liquid Chromatography/Atmospheric Pressure Ionization/Tandem Mass Spectrometry (HPLC/API/MS/MS) in Drug Metabolism and Toxicology. Current Drug Metabolism. 7(8). 837–852. 43 indexed citations

12.

Kamel, Amin, John P. Davis, Michael J. Potchoiba, & Chandra Prakash. (2006). Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: Characterization of a novel oxidative pathway. Xenobiotica. 36(2-3). 235–258. 10 indexed citations

13.

Kamel, Amin & Chandra Prakash. (2006). A Personal Tribute. Current Drug Metabolism. 7(8). ii–ii. 1 indexed citations

14.

Miao, Zhuang, Amin Kamel, & Chandra Prakash. (2005). CHARACTERIZATION OF A NOVEL METABOLITE INTERMEDIATE OF ZIPRASIDONE IN HEPATIC CYTOSOLIC FRACTIONS OF RAT, DOG, AND HUMAN BY ESI-MS/MS, HYDROGEN/DEUTERIUM EXCHANGE, AND CHEMICAL DERIVATIZATION. Drug Metabolism and Disposition. 33(7). 879–883. 32 indexed citations

15.

Nassar, Alaa-Eldin F., et al.. (2004). Improvingthe decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discovery Today. 9(24). 1055–1064. 53 indexed citations

16.

Nassar, Alaa-Eldin F., et al.. (2004). Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discovery Today. 9(23). 1020–1028. 141 indexed citations

17.

Kamel, Amin, Kathleen S. Zandi, & Walter Massefski. (2003). Identification of the degradation product of ezlopitant, a non-peptidic substance p antagonist receptor, by hydrogen deuterium exchange, electrospray ionization tandem mass spectrometry (ESI/MS/MS) and nuclear magnetic resonance (NMR) spectroscopy. Journal of Pharmaceutical and Biomedical Analysis. 31(6). 1211–1222. 11 indexed citations

18.

Prakash, Chandra, et al.. (2000). Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology. 49(S1). 35–42. 98 indexed citations

19.

Kamel, Amin, et al.. (2000). Narrow-bore high-performance liquid chromatography in combination with ionspray tandem mass spectrometry for the determination of the substance P receptor antagonist ezlopitant and its two active metabolites in plasma. Journal of Chromatography B Biomedical Sciences and Applications. 748(1). 179–188. 4 indexed citations

20.

Kamel, Amin & Chandra Prakash. (1997). Determination of the substance P receptor antagonist CP-122, 721 in plasma by narrow-bore high-performance liquid chromatography-ionspray tandem mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 700(1-2). 139–146. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact